PMID- 10845554
OWN - NLM
STAT- MEDLINE
DCOM- 20000627
LR  - 20191025
IS  - 0262-0898 (Print)
IS  - 0262-0898 (Linking)
VI  - 17
IP  - 7
DP  - 1999
TI  - Expression of matrix metalloproteinases and their inhibitors in human brain 
      tumors.
PG  - 555-66
AB  - Sixty human brain tumors, classified according to the New World Health 
      Organization (WHO) classification including, grade I schwannomas, meningiomas and 
      pilocytic astrocytomas, grade II astrocytomas, grade III anaplastic astrocytomas, 
      grade IV glioblastomas, grade III anaplastic oligodendrogliomas and grade IV 
      glioblastomas and lung and melanoma metastases were analyzed for the expression 
      of three matrix metalloproteinases (MMPs), two tissue inhibitors of MMPs (TIMPs) 
      and for MMP activity. Some correlation was found between MMP expression and the 
      degree of malignancy. Western blotting analysis revealed a more uniform pattern 
      of distribution of MMP-2 (gelatinase A) than of MMP-9 (gelatinase B) and MMP-12 
      (metalloelastase) among tumors. MMP-9 levels were found to be significantly 
      higher in grade III anaplastic astrocytomas and anaplastic oligodendrogliomas 
      than those in grade I schwannomas and meningiomas. Anaplastic astrocytomas and 
      Grade IV glioblastomas expressed significantly higher levels MMP-12 than grade I 
      meningiomas. All sixty tumors showed a similar pattern of activity in zymography, 
      proMMP-9 being the major species detected. Interestingly, TIMP-1 and TIMP-2 
      expression levels were especially low in tumors of grade II and grade III but 
      significantly higher in tumors of grade I, particularly in schwannomas. Taken 
      together, these data suggest that: 1) a balance between MMPs and TIMPs has an 
      important role to play in human brain tumors; 2) TIMP expression may be valuable 
      markers for tumor malignancy.
FAU - Kachra, Z
AU  - Kachra Z
AD  - Laboratoire de medecine moleculaire, Centre de cancerologie Charles-Bruneau, 
      Hopital Ste-Justine-UQAM, Montreal, Quebec, Canada.
FAU - Beaulieu, E
AU  - Beaulieu E
FAU - Delbecchi, L
AU  - Delbecchi L
FAU - Mousseau, N
AU  - Mousseau N
FAU - Berthelet, F
AU  - Berthelet F
FAU - Moumdjian, R
AU  - Moumdjian R
FAU - Del Maestro, R
AU  - Del Maestro R
FAU - Beliveau, R
AU  - Beliveau R
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Clin Exp Metastasis
JT  - Clinical & experimental metastasis
JID - 8409970
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Tissue Inhibitor of Metalloproteinase-1)
RN  - 127497-59-0 (Tissue Inhibitor of Metalloproteinase-2)
RN  - 9000-70-8 (Gelatin)
RN  - EC 3.4.24.- (Metalloendopeptidases)
RN  - EC 3.4.24.24 (Matrix Metalloproteinase 2)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
RN  - EC 3.4.24.65 (MMP12 protein, human)
RN  - EC 3.4.24.65 (Matrix Metalloproteinase 12)
SB  - IM
MH  - Astrocytoma/chemistry/pathology
MH  - Biomarkers, Tumor
MH  - Blotting, Western
MH  - Brain Neoplasms/*chemistry/pathology
MH  - Gelatin/metabolism
MH  - Glioblastoma/chemistry/pathology
MH  - Humans
MH  - Matrix Metalloproteinase 12
MH  - Matrix Metalloproteinase 2/analysis
MH  - Matrix Metalloproteinase 9/analysis
MH  - Meningeal Neoplasms/chemistry/pathology
MH  - Meningioma/chemistry/pathology
MH  - Metalloendopeptidases/*analysis
MH  - Neoplasm Invasiveness
MH  - Neoplasm Proteins/*analysis
MH  - Neurilemmoma/chemistry/pathology
MH  - Tissue Inhibitor of Metalloproteinase-1/*analysis
MH  - Tissue Inhibitor of Metalloproteinase-2/*analysis
EDAT- 2000/06/14 09:00
MHDA- 2000/07/06 11:00
CRDT- 2000/06/14 09:00
PHST- 2000/06/14 09:00 [pubmed]
PHST- 2000/07/06 11:00 [medline]
PHST- 2000/06/14 09:00 [entrez]
AID - 10.1023/a:1006760632766 [doi]
PST - ppublish
SO  - Clin Exp Metastasis. 1999;17(7):555-66. doi: 10.1023/a:1006760632766.